Your email has been successfully added to our mailing list.

×
0.012370113805047 0.012370113805047 -0.000989609104403739 0.0588817417120238 0.0539336961900049 0.0291934685799109 -0.0113805047006433 -0.012864918357249
Stock impact report

CareDx to acquire Naveris in up to $260M oncology diagnostics deal [Seeking Alpha]

CareDx, Inc. (CDNA) 
Last caredx, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.caredxinc.com
Company Research Source: Seeking Alpha
Naveris, which develops blood-based tests for viral-mediated cancers, reported unaudited revenue of about $34 million in 2025. CareDx said the deal is expected to be neutral to its 2026 adjusted EBITDA guidance. The transaction is expected to close in the third quarter, subject to customary conditions. Source: Press Release Fresh Stock Ideas, Every Day More on CareDx CareDx Q1 2026 Earnings Preview Stocks to watch after market on Wednesday: CDNA, JBHT, SLG, QDEL Recommended For You Show less Read more
Impact Snapshot
Event Time:
CDNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CDNA alerts
Opt-in for
CDNA alerts

from News Quantified
Opt-in for
CDNA alerts

from News Quantified